Lykos Therapeutics Announces Reorganization to Address FDA's Recent Decision on Midomafetamine Capsules for PTSD; Reducing workforce by ~75%
- Pharmaceutical industry veteran and former Janssen executive Dr. David Hough appointed senior medical advisor to oversee clinical and regulatory
- Lykos to significantly reduce workforce, streamlining organization around clinical development and regulatory engagement
- MAPS founder Dr. Rick Doblin to exit from Lykos Board
Lykos Therapeutics ("Lykos"), a company dedicated to transforming mental healthcare, today announced a reorganization to best support the company as it works to address the resubmission of its new drug application ("NDA") for midomafetamine capsules for the treatment of post-traumatic stress disorder ("PTSD") in adults.As part of the changes, Dr. David Hough will lead and oversee the clinical development program and FDA engagement regarding the resubmission of midomafetamine. Dr. Hough previously was Vice President of Research and Development at J&J Innovative Medicine (a Johnson & Johnson company). He served in various leadership roles over 17 years, including as the compound development team leader for INVEGA (paliperidone), INVEGA SUSTENNA, INVEGA TRINZA, as well as the compound development team leader for SPRAVATO® (esketamine nasal spray), a position in which he was responsible for all medical, scientific, manufacturing, quality, preclinical, and commercial aspects of the program.